SynCardia Facebook SynCardia Twitter SynCardia LInkedIn SynCardia Google Plus SynCardia Youtube

SynCardia Systems, Inc.

Press Release:

FDA Approves the SynCardia Total Artificial Heart With SynHall Valves

SynCardia Systems, Inc., now controls last key component in heart manufacturing.

SynCardia Systems, Inc., received FDA approval to manufacture the SynCardia Total Artificial Heart with SynHall™ valves. The OK gives the company control over the two critical components for heart manufacturing: The valves and the unique formula for segmented polyurethane solution (SPUS), which is manufactured only by SynCardia. SynCardia Systems, Inc., received FDA approval to manufacture the SynCardia Total Artificial Heart with SynHall™ valves. The OK gives the company control over the two critical components for heart manufacturing: The valves and the unique formula for segmented polyurethane solution (SPUS), which is manufactured only by SynCardia. TUCSON, Ariz. – Aug. 5, 2014 – SynCardia Systems, Inc. received approval July 2, 2014 from the United States Food and Drug Administration (FDA) for the SynCardia temporary Total Artificial Heart with SynHall™ valves, giving the company control over the last key component to manufacture the Total Artificial Heart.

FDA approval follows SynCardia’s receipt of the CE Mark for European use of the SynHall valves only in the SynCardia Total Artificial Heart on April 17, 2014. Health Canada approval was received for the same purpose on July 28, 2014.

The SynHall valves – only for use in the SynCardia Heart – are of the same design, materials and nearly identical manufacturing processes as the tilting-disk valves that have always been used in the Total Artificial Heart.

Made of titanium and pyrolytic carbon, these robust valves have never failed in more than 1,300 implants of the SynCardia Total Artificial Heart, accounting for well over 5,000 valves and over 30 years of use.

“We’re delighted that the SynHall valves passed the FDA’s rigorous approval process,” says Michael P. Garippa, SynCardia CEO and President.

The company also controls manufacture of segmented polyurethane solution (SPUS), which is used in the SynCardia Total Artificial Heart’s housings, diaphragms and connectors. SynCardia is the only source of SPUS in the world.

###

 

About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the temporary Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.

Follow SynCardia: Facebook | Twitter | LinkedIn | Google+

SynCardia Contact:
Janelle Drumwright, jdrumwright@syncardia.com, (520) 547-7463

Search offcanvas